Endocrine and Radiological Studies in Patients with Molecularly Confirmed CHARGE Syndrome

Asakura, Yumi; Toyota, Yuko; Muroya, Koji; Kurosawa, Kenji; Fujita, Kazutoshi; Aida, Noriko; Kawame, Hiroshi; Kosaki, Kenjiro; Adachi, Masanori

doi:10.1210/jc.2007-1419

Cited by 42 publications

(63 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, our series was biased, and we analyzed only a small number of patients with this syndrome because patients with CHARGE syndrome and CHD7 mutations were more likely to undergo imaging. 19 Thus, additional studies of the incidence and severity of CHARGE syndrome without CHD7 mutations are mandatory; however, we tentatively concluded that routine assessment of the basiocciput in patients with CHARGE syndrome is helpful to exclude potentially life-threatening basilar invagination regardless of the presence or absence of CHD7 mutations.…”

Section: (ϫ35)mentioning

confidence: 79%

Abnormal Basiocciput Development in CHARGE Syndrome

Fujita¹,

Aida²,

Asakura³

et al. 2008

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

BACKGROUND AND PURPOSE:The causative gene of the common congenital malformation referred to as CHARGE syndrome is CHD7. Affected individuals often undergo head and neck imaging to assess abnormalities of the olfactory structures, hypothalamus-pituitary axis, and inner ear. We encountered a few children with severe hypoplasia of the basiocciput during a radiologic assessment of patients with CHARGE syndrome. To our knowledge, this anomaly has not been reported. Our purpose was to evaluate the incidence and severity of this anomaly in this syndrome.

show abstract

Section: (ϫ35)mentioning

confidence: 79%

Abnormal Basiocciput Development in CHARGE Syndrome

Fujita¹,

Aida²,

Asakura³

et al. 2008

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

show abstract

“…There is a higher percentage of stop codons in our cohort than in the published literature (52.7% vs. 35.4%). Of 189 published mutations, there were 35.4% stop mutations, 33.3% frameshifts, 7%-15% splicing mutations, 6%-13% missense mutations, and 3% large deletion/duplications (Vissers et al, 2004;Felix et al, 2006;Jongmans et al, 2006;Lalani et al, 2006;Sanlaville et al, 2006;Aramaki et al, 2007;Vuorela et al, 2007;Asakura et al, 2008;Bergman et al, 2008;Gennery et al, 2008;Wincent et al, 2008).…”

Section: Discussionmentioning

confidence: 99%

“…DNA sequencing detects CHD7 mutations in *58%-64% of patients clinically diagnosed with CHARGE syndrome (Vissers et al, 2004;Jongmans et al, 2006;Lalani et al, 2006). Of the CHD7 mutations reported thus far, *70% are nonsense or frameshift, 6%-13% are missense, and 7%-15% are splice site mutations (Vissers et al, 2004;Felix et al, 2006;Jongmans et al, 2006;Lalani et al, 2006;Sanlaville et al, 2006;Aramaki et al, 2007;Vuorela et al, 2007;Asakura et al, 2008;Bergman et al, 2008;Gennery et al, 2008;Wincent et al, 2008). Partial and whole gene deletions or duplications are rare, accounting for 3%-4% of pathogenic CHD7 mutations (Aramaki et al, 2006;Vuorela et al, 2007;Bergman et al, 2008;Wincent et al, 2008).…”

mentioning

confidence: 99%

Mutations in the CHD7 Gene: The Experience of a Commercial Laboratory

Bartels

Scacheri²,

White³

et al. 2010

Genetic Testing and Molecular Biomarkers

View full text Add to dashboard Cite

CHARGE syndrome is an autosomal dominant multisystem disorder caused by mutation in the CHD7 gene, encoding chromodomain helicase DNA-binding protein 7. Molecular diagnostic testing for CHD7 mutation has been available in a clinical setting since 2005. We report here the results from the first 642 unrelated proband samples submitted for testing. Thirty-two percent (n ¼ 203) of patient samples had a heterozygous pathogenic variant identified. The lower mutation rate than that published for well-characterized clinical samples is likely due to referral bias, as samples submitted for clinical testing may be for ''rule-out'' diagnoses, rather than solely to confirm clinical suspicion. We identified 159 unique pathogenic mutations, and of these, 134 mutations were each seen in a single individual and 25 mutations were found in two to five individuals (n ¼ 69). Of the 203 mutations, only 9 were missense, with 107 nonsense, 69 frameshift, and 15 splice-site mutations likely leading to haploinsufficiency at the cellular level. An additional 72 variations identified in the 642 tested samples (11%) were considered to have unknown clinical significance. Copy number changes (deletion/duplication of the entire gene or one/several exons) were found to account for a very small number of cases (n ¼ 3). This cohort represents the largest CHARGE syndrome sample size to date and is intended to serve as a resource for clinicians, genetic counselors, researchers, and other diagnostic laboratories.

show abstract

“…In this article, we give an overview of all CHD7 missense variants reported in the literature before 15 June 2011 [Asakura et al, 2008;Bartels et al, 2010;Bergman et al, 2011a, b;Dauber et al, 2010;De Arriba Munoz et al, 2011;Delahaye et al, 2007;Felix et al, 2006;Feret et al, 2010;Fujita et al, 2009;Gao et al, 2007;Holak et al, 2008;Jongmans et al, 2006Jongmans et al, , 2008Jongmans et al, , 2009Kim et al, 2008;Lalani et al, 2006;Pauli et al, 2012;Vissers et al, 2004;Vuorela et al, 2007;Wessels et al, 2010;Wincent et al, 2008] and the variants that were reported in the NCBI Single Nucleotide Polymorphism database (http://www.ncbi.nlm.nih.gov/SNP, dbSNP build 132) with frequency data (n = 104, Supp. Table S1).…”

Section: Inclusion Of Chd7 Missense Variantsmentioning

confidence: 99%

A novel classification system to predict the pathogenic effects of CHD7 missense variants in CHARGE syndrome

et al. 2012

View full text Add to dashboard Cite

CHARGE syndrome is characterized by the variable occurrence of multisensory impairment, congenital anomalies, and developmental delay, and is caused by heterozygous mutations in the CHD7 gene. Correct interpretation of CHD7 variants is essential for genetic counseling. This is particularly difficult for missense variants because most variants in the CHD7 gene are private and a functional assay is not yet available. We have therefore developed a novel classification system to predict the pathogenic effects of CHD7 missense variants that can be used in a diagnostic setting. Our classification system combines the results from two computational algorithms (PolyPhen-2 and Align-GVGD) and the prediction of a newly developed structural model of the chromo-and helicase domains of CHD7 with segregation and phenotypic data. The combination of different variables will lead to a more confident prediction of pathogenicity than was previously possible. We have used our system to classify 145 CHD7 missense variants. Our data show that pathogenic missense mutations are mainly present in the middle of the CHD7 gene, whereas benign variants are mainly clustered in the 5 and 3 regions. Finally, we show that CHD7 missense mutations are, in general, associated with a milder phenotype than truncating mutations.

show abstract

Endocrine and Radiological Studies in Patients with Molecularly Confirmed CHARGE Syndrome

Cited by 42 publications

References 17 publications

Abnormal Basiocciput Development in CHARGE Syndrome

Abnormal Basiocciput Development in CHARGE Syndrome

Mutations in the CHD7 Gene: The Experience of a Commercial Laboratory

A novel classification system to predict the pathogenic effects of CHD7 missense variants in CHARGE syndrome

Contact Info

Product

Resources

About